ImmunoCellular Therapeutics To Present At Lazard Capital Markets 9th Annual Healthcare Conference On November 14th

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the Lazard Capital Markets 9 th Annual Healthcare Conference on November 14, 2012 at 11:00 am ET at the Pierre Hotel in New York City.

To access the live audio webcast of the Lazard presentation, please log on through a link located in the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Investors, Webcasts & Presentations tab. A replay of the webcasts will be available one hour after the conclusion of the live event.

In addition, Peter Ho, PhD, Director of Business Development, will present a company overview on November 14, 2012 at the 18th annual BIO-Europe® international partnering conference on November 14, 2012 at 9:30 GMT at the CCH Congress Center, Hamburg, Germany.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about ImmunoCellular, please visit www.imuc.com.

Copyright Business Wire 2010

If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

4 Stocks Under $10 to Trade for Breakouts

4 Stocks Under $10 to Trade for Breakouts